Bing Yao, ArriVent Biopharma CEO
January 26, 2024 03:14 AM ESTUpdated 01:02 PM
Financing

Ar­riVent prices $175M IPO in back-to-back on­col­o­gy biotech list­ings

Kyle LaHucik

Senior Reporter

Ar­riVent Bio­phar­ma will join the Nas­daq on Fri­day morn­ing in a strong start to biotech’s first batch of ini­tial pub­lic of­fer­ings this year.
The Penn­syl­va­nia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times